An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary) ; Tc 99m sulfur colloid
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 04 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 04 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
- 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.